Cargando…
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075468/ https://www.ncbi.nlm.nih.gov/pubmed/32206190 http://dx.doi.org/10.18632/oncotarget.27512 |
| _version_ | 1783507046026444800 |
|---|---|
| author | Goldenberg, David M. Cardillo, Thomas M. Govindan, Serengulam V. Rossi, Edmund A. Sharkey, Robert M. |
| author_facet | Goldenberg, David M. Cardillo, Thomas M. Govindan, Serengulam V. Rossi, Edmund A. Sharkey, Robert M. |
| author_sort | Goldenberg, David M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7075468 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70754682020-03-23 Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* Goldenberg, David M. Cardillo, Thomas M. Govindan, Serengulam V. Rossi, Edmund A. Sharkey, Robert M. Oncotarget Correction Impact Journals LLC 2020-03-10 /pmc/articles/PMC7075468/ /pubmed/32206190 http://dx.doi.org/10.18632/oncotarget.27512 Text en Copyright: © 2020 Goldenberg et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Goldenberg, David M. Cardillo, Thomas M. Govindan, Serengulam V. Rossi, Edmund A. Sharkey, Robert M. Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
| title | Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
| title_full | Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
| title_fullStr | Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
| title_full_unstemmed | Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
| title_short | Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
| title_sort | correction: trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (immu-132), an antibody-drug conjugate (adc)* |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075468/ https://www.ncbi.nlm.nih.gov/pubmed/32206190 http://dx.doi.org/10.18632/oncotarget.27512 |
| work_keys_str_mv | AT goldenbergdavidm correctiontrop2isanoveltargetforsolidcancertherapywithsacituzumabgovitecanimmu132anantibodydrugconjugateadc AT cardillothomasm correctiontrop2isanoveltargetforsolidcancertherapywithsacituzumabgovitecanimmu132anantibodydrugconjugateadc AT govindanserengulamv correctiontrop2isanoveltargetforsolidcancertherapywithsacituzumabgovitecanimmu132anantibodydrugconjugateadc AT rossiedmunda correctiontrop2isanoveltargetforsolidcancertherapywithsacituzumabgovitecanimmu132anantibodydrugconjugateadc AT sharkeyrobertm correctiontrop2isanoveltargetforsolidcancertherapywithsacituzumabgovitecanimmu132anantibodydrugconjugateadc |